Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Nurix Therapeutics, Inc. is planning meetings with securities analysts, investors and others beginning on September 3, 2025 and will use an updated investor presentation in those discussions. The presentation focuses on clinical development plans for bexobrutideg (NX-5948), an investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase that is in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies. The investor presentation is provided as Exhibit 99.1 and is furnished under a Regulation FD disclosure, rather than being treated as filed under the securities laws.
Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel. The board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., who is already a board member and a member of the Clinical and Commercialization Committee, to serve as chair of that committee effective September 1, 2025. The change is administrative and focused on committee leadership; no financial data, transactions, or other operational actions are disclosed in the filing.